Farmindustria, 5,000 new hires in one year, +1% employees
Massimo Scaccabarozzi was today unanimously elected to the Presidency of Farmindustria for the third consecutive term (2015-2017) by the Assembly of
Association.
Scaccabarozzi – Milanese, 55 years old, married, two children, graduated in Pharmacy – is President and CEO of Janssen-Cilag. This was announced in a press release by Farmindustria which underlines how Scaccabarozzi has been President of Farmindustria since June 2011 and a member of the General Council of Confindustria.
The Assembly also elected the Presidential Committee made up of five Vice-Presidents: Lucia Aleotti (Menarini); Maurizio de Cicco (Roche); Francesco De Santis (Italfarmaco); Daniele Finocchiaro (GlaxoSmithKline); Emilio Stefanelli (Savio National Biochemical Institute).
The Presidential Committee also includes: Alberto Chiesi (Chiesi Farmaceutici), Stefano Golinelli (AlfaSigma), Luciano Grottola (Ecupharma), Antonio Messina (Merck Serono), Massimo Giorgio Visentin (Pfizer), Alexander Zehnder (Sanofi).
The new team will illustrate the programmatic lines for the two-year period 2015-2017 during the Farmindustria public assembly, which will take place tomorrow, Thursday 2 July, in Rome starting at 10.30, at the Argentina Theater and which it will be possible to follow in live streaming on the Doctor33 website by clicking here.
Thursday, 02 July 2015 – Doctor33
Farmindustria, 5,000 new hires in one year, +1% employees
L
Thanks also to the Jobs Act, employment in the pharmaceutical sector is no longer marking time and the 5,000 new hires – half of those under 30 – have exceeded outgoing workers in the last 12 months, with an increase (+1%) of number of employees. Investments increased by 200 million euros (+11%). Exports grew again (+6% in 2014, after +14% in 2013 and +13% in 2012) by 1.2 billion in just one year. These are some of the topics at the center of the debate in the Farmindustria Public Assembly, taking place in Rome at the Teatro Argentina.
Today - notes the association of pharmaceutical industries - a new phase is on the horizon. There are 7,000 medicines in development, mainly biotech, which concern cancer, cardiovascular diseases, diabetes, HIV. Increasingly personalized drugs that will change the history of several serious diseases. A phenomenon in which Italy also participates with its centers of excellence, for example for oncology, rare diseases, vaccines, biotech drugs and advanced therapies.
The game hasn't been won, but important goals have been scored thanks to an efficient innovation network that creates health and value. A revolution that requires rethinking governance to ensure the sustainability of the system, argues Farmindustria.
The benefits for patients' health go hand in hand with the industrial role of drug companies. This is demonstrated by the increase in production (+4.5%), which reached 28.7 billion euros, and the all-time high reached by exports (72% of production) with 21 billion. From 2010 to 2014, our country was the first in the world for growth in the value of exports of medicines and vaccines. Results that have strengthened the second position after Germany among the nations producing medicines in the European Union.
The Italy of medicines, with its 63,000 employees, 174 factories in the area and 2.5 billion in investments, confirms itself as the European hub of the sector. And it wants to become the world hub.
“Successes achieved by companies that are the pride of Made in Italy – affirms Massimo Scaccabarozzi, president of Farmindustria – but which it would be wrong to take for granted, especially in a highly competitive world context. This is why there is a need for stability, guaranteed in the last 2 years with certain rules, to be confirmed and consolidated to encourage investment and innovation. Italy is emerging from the crisis. And the pharmaceutical industry has been one of the co-protagonists of the country's relaunch. There are decisive challenges ahead of us - concludes Scaccabarozzi - By working together, side by side, with the institutions and the other players in the system, we will be able to overcome them for a future with great opportunities. For everyone, starting with the patients”.
Article published on: 02/07/2015 – adnkronos
Related news: Poletti: "Pharmaceutical sector is Italian excellence, 'competition' with Germany"
